skin cancer
DermTech Stock Soars on News of Additional Coverage for Melanoma Detection Test
The molecular diagnostics firm said two payors with 1.2 million members in New York and Hawaii will cover DermTech's noninvasive testing platform.
Tempus, Kartos Therapeutics to Develop CDx for Skin Cancer Therapy
The test will run on Tempus' xT platform and will be used to identify patients with TP53 wild-type Merkel cell carcinoma who may be eligible for treatment with the drug.
SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay
The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries.
The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories.
Local Coverage Determinations Roundup: Castle Bio, SkylineDx
Palmetto GBA released a final local coverage determination that covers tests from Castle Biosciences and SkylineDx.
May 9, 2022
Castle Biosciences Q1 Revenues Grow 18 Percent
May 4, 2022
DermTech Posts 48 Percent Jump in Q1 Revenues
Feb 28, 2022
Castle Biosciences Q4 Revenues Grow 45 Percent
Nov 9, 2021
Dermtech Q3 Revenues Rise 122 Percent
Nov 8, 2021
Castle Biosciences Q3 Revenues Rise 54 Percent
Oct 27, 2021
Aug 9, 2021
Castle Biosciences Q2 Revenues Rise 79 Percent
May 11, 2021
May 10, 2021
Castle Biosciences Q1 Revenues Up 31 Percent
Mar 8, 2021
Castle Biosciences Q4 Revenues Down 2 Percent
Mar 5, 2021